Belvedere Trading
MTCR

Belvedere Trading’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Belvedere Trading’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29,267
Closed -$102K – 708
2021
Q3 		$102K Buy
+29,267
New +$91.3K ﹤0.01% 355

Other funds holding MTCR

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Belvedere Trading's MTCR Position: Q4 2021 in Review

Belvedere Trading sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2021, closing a stake of 29,267 shares — an estimated $102K sold.

Belvedere Trading first reported a position in MTCR in Q3 2021 and held it in 1 quarter. The position peaked at $102K in Q3 2021. 31 funds tracked by Wall St. Rank hold MTCR as of Q4 2021.

  • Belvedere Trading reported no remaining Metacrine, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Belvedere Trading sold 29,267 Metacrine, Inc. Common Stock shares in Q4 2021, an estimated $102K.
  • Belvedere Trading first reported a position in Metacrine, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Belvedere Trading's Metacrine, Inc. Common Stock position peaked at $102K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.